Researchers at Origenis GmbH have patented pyrazolotriazine derivatives acting as inhibitors of cyclin-dependent kinase (CDK), particularly CDK2 and CDK9.
Sirnaomics Ltd. is advancing lead siRNA candidate STP-705 for the treatment of squamous cell carcinoma in situ into late-stage clinical testing after sharing encouraging phase II trial results with the U.S. FDA in an end-of-phase II meeting. The company plans to move forward in 2023 with a single-dose study as a subgroup of subjects in a large phase III study. Positive results will provide the basis for completion of this large registrational phase III trial.
Curocell Inc. is inching closer to realizing Korea’s first domestically developed CAR T therapy, presenting “encouraging” interim phase II trial results for anbalcabtagene-autoleucel at the International Conference on Malignant Lymphoma in Lugano, Switzerland.
New isoindolines acting as mismatch repair endonuclease PMS2 inhibitors have been reported in a Neophore Ltd. patent as useful for the treatment of cancer.
Geode Therapeutics Inc. and Xtalpi Inc. have jointly developed phosphatidylinositol 3-kinase γ (PI3Kγ) inhibitors reported to be useful for the treatment of cancer.
Research at Kumquat Biosciences Inc. has led to the development of Hetero-atom containing compounds described as tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and (PTPN2; TCPTP) inhibitors and reported to be useful for the treatment of cancer.
TG Immunopharma Co. Ltd. has announced clearance by the FDA for a clinical trial of TGI-6, a bispecific antibody targeting unique tumor-associated antigens (TAA) and CD3 molecules simultaneously, for solid tumors.
Researchers from Innate Pharma SA recently presented preclinical data for IPH-6501, a novel CD20-targeting tetraspecific antibody-based natural killer (NK)-cell engager therapeutic being developed for the treatment of patients with B-cell non-Hodgkin lymphoma (B-NHL).
Avenda Health Inc. reported new study results showing its Unfold AI platform, which uses artificial intelligence (AI) to map a tumor’s location within the prostate, encapsulates all of the clinically significant cancer present in the gland more effectively than standard care.
TYK Medicines Inc. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising cereblon (CRBN) binding moieties covalently linked to EGFR (HER1; erbB1) binding moieties reported to be useful for the treatment of cancer, infections, cardiovascular, immunological, inflammatory and metabolic diseases.
RSS
